Survival Benefit of Compound Kushen Injection in the Treatment of Advanced Colorectal Cancer

Combined with other malignant primary tumors;

Immunohistochemistry/polymerase chain reaction/second-generation sequencing results suggest MSI-H/dMMR patients;

Patients with recurrence and metastasis within 6 months after radical tumor surgery;

Patients who have previously or are undergoing cancer immunotherapy ; Patients undergoing radiation therapy;